Literature DB >> 20390389

Need to improve thromboprophylaxis across the continuum of care for surgical patients.

Alpesh N Amin1, Jay Lin, Amy Ryan.   

Abstract

INTRODUCTION: Prophylaxis for venous thromboembolism (VTE) is underused following major surgery and frequently stopped at hospital discharge despite short stays and high VTE risk for several weeks postsurgery. We evaluated inpatient and postdischarge prophylaxis in patients who underwent major abdominal or orthopedic surgery.
METHODS: Patient records were assessed for anticoagulant use by cross-matching data from the Premier's Perspective discharge database with the i3/Ingenix LabRx outpatient and inpatient database from January 2005 to December 2007. Abdominal or orthopedic surgery patients at risk of VTE according to the 2004 American College of Chest Physicians guidelines and with no contraindications to anticoagulation were included.
RESULTS: A total of 14,009 eligible surgical discharges were analyzed. Only 27.9% of the 10,698 abdominal surgery patients received anticoagulation in hospital. Most inpatients received unfractionated heparin (12.3% of the total abdominal surgery population) or enoxaparin (11.8%). Of the 3311 orthopedic surgery patients, 91.1% received in-hospital anticoagulation. Similar proportions of patients received enoxaparin (32.1%), warfarin (31.1%), or other agents (28.0%). Only 1.2% of abdominal surgery patients had an anticoagulant prescription filled 30 days postdischarge. Although orthopedic surgery outpatients had higher anticoagulation rates, only 54.4% had filled a prescription 30 days postdischarge with 31.1% receiving warfarin, 18.5% receiving enoxaparin, and 4.8% receiving other anticoagulants. The higher prophylaxis rate in orthopedic patients may reflect the high VTE risk in orthopedic surgery patients and increased awareness among orthopedic surgeons.
CONCLUSION: This real-world study highlights the underuse of thromboprophylaxis in hospitalized surgical patients, especially following abdominal surgery. Furthermore, a considerable proportion of these patients do not receive postdischarge anticoagulation despite guideline recommendations. Further efforts are needed to improve anticoagulant use, particularly in the outpatient setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390389     DOI: 10.1007/s12325-010-0015-8

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  7 in total

1.  Risk factors for post-discharge venous thromboembolism in patients undergoing colorectal resection: a NSQIP analysis.

Authors:  N Alhassan; M Trepanier; C Sabapathy; P Chaudhury; A S Liberman; P Charlebois; B L Stein; L Lee
Journal:  Tech Coloproctol       Date:  2018-12-19       Impact factor: 3.781

2.  Body Contouring in Massive Weight Loss Patients Receiving Venous Thromboembolism Chemoprophylaxis: A Systematic Review.

Authors:  Christine Yin; Phoebe B McAuliffe; Jocellie E Marquez; Christopher D Liao; Vasileios Vasilakis; Jewel Estrella; Nicos Labropoulos; Sami U Khan
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-08-13

3.  Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery.

Authors:  James C Iannuzzi; Aaron S Rickles; Kristin N Kelly; Fergal J Fleming; James G Dolan; John R T Monson; Katia Noyes
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

4.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Seth Felder; Morten Schnack Rasmussen; Ray King; Bradford Sklow; Mary Kwaan; Robert Madoff; Christine Jensen
Journal:  Cochrane Database Syst Rev       Date:  2019-03-27

5.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Seth Felder; Morten Schnack Rasmussen; Ray King; Bradford Sklow; Mary Kwaan; Robert Madoff; Christine Jensen
Journal:  Cochrane Database Syst Rev       Date:  2019-08-26

6.  Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.

Authors:  Francesco Paciullo; Loredana Bury; Patrizia Noris; Emanuela Falcinelli; Federica Melazzini; Sara Orsini; Carlo Zaninetti; Rezan Abdul-Kadir; Deborah Obeng-Tuudah; Paula G Heller; Ana C Glembotsky; Fabrizio Fabris; Jose Rivera; Maria Luisa Lozano; Nora Butta; Remi Favier; Ana Rosa Cid; Marc Fouassier; Gian Marco Podda; Cristina Santoro; Elvira Grandone; Yvonne Henskens; Paquita Nurden; Barbara Zieger; Adam Cuker; Katrien Devreese; Alberto Tosetto; Erica De Candia; Arnaud Dupuis; Koji Miyazaki; Maha Othman; Paolo Gresele
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

7.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Seth Felder; Morten Schnack Rasmussen; Ray King; Bradford Sklow; Mary Kwaan; Robert Madoff; Christine Jensen
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.